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Summary
Some patients with b thalassaemia experience non-progressive creatinine
increases with deferasirox, mostly within normal limits; the mechanisms
involved are not fully elucidated. The effects of deferasirox on renal haemo-
dynamics, including glomerular filtration rate (GFR) and renal plasma flow
(RPF), were investigated in a Phase I, open-label study in b thalassaemia
major patients with iron overload. Patients received deferasirox 30 mg/kg/d
up to Week 8, followed by a 2-week washout period, and extended treat-
ment up to Week 104 with a 4-week washout period. In the short-term
study (n = 11), mean GFR and RPF declined from baseline to Week 8
(mean [%] change:92 [95%] and 1057 ml/min [178%], respec-
tively). A similar pattern was observed during the long-term study (n = 5);
mean GFR and RPF decreased up to Week 52 (191 [177%] and
1556 ml/min [261%]), with similar change at Week 104 (184
[172%] and 1159 ml/min [196%]). Measures returned to baseline
values after each washout. Serum creatinine and creatinine clearance fol-
lowed a similar pattern. Effects of deferasirox on renal haemodynamics
were mild and reversible for up to 2 years of treatment, with no progres-
sive worsening of renal function over time. www.clinicaltrials.gov:
NCT00560820.
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Transfusion-dependent patients with b thalassaemia major
now have longer life expectancies as a result of improved
treatment outcomes (Borgna-Pignatti et al, 2004; Voskaridou
et al, 2012). Complications that were previously less promi-
nent, such as changes in renal function, which may increase
in frequency as patients age or with increased transfusion
duration, are becoming more apparent (Mohkam et al, 2008;
Ponticelli et al, 2010; Bhandari & Galanello, 2012). While
some studies suggest the influence of iron chelation therapy
on renal haemodynamics (Economou et al, 2010; Hamed &
ElMelegy, 2010), others implicate the inherent effects of the
disease (i.e. chronic anaemia) and the consequences of trans-
fusion-related iron overload (Koliakos et al, 2003; Sadeghi-
Bojd et al, 2008). In a study of 91 non-diabetic patients with
b thalassaemia and normal blood pressure, serum urea, cre-
atinine and electrolytes, increased levels of urinary markers
indicative of renal tubular dysfunction correlated positively
with markers of iron overload but not chronic anaemia or
chelation therapy (Koliakos et al, 2003). Collectively, evi-
dence suggests that alterations in renal haemodynamics in
patients with b thalassaemia are unlikely to be attributable to
a single cause.
Given the lifelong dependence on transfusions, long-term
chelation therapy will be required, hence a long-term man-
ageable safety profile of chelators is a necessity. Deferasirox
(Exjade, Novartis Pharmaceuticals, 2013) has demonstrated
significant short- and long-term efficacy in effectively reduc-
ing and preventing hepatic and cardiac iron burden in
patients with thalassaemia and other chronic anaemias
(Galanello et al, 2006; Cappellini et al, 2006, 2010, 2011; Vi-
chinsky et al, 2007; Porter et al, 2008; Pennell et al, 2010,
2012; Vichinsky et al, 2011). The deferasirox clinical trial
programme also highlighted that some patients experience
dose-dependent serum creatinine increases >33% above base-
line values. However, observed creatinine elevations in stud-
ies up to 5 years of duration were mostly within normal
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limits, non-progressive and reversible with dose reduction
and/or interruption (Cappellini et al, 2006, 2010, 2011; Gala-
nello et al, 2006; Vichinsky et al, 2007; Porter et al, 2008;
Pennell et al, 2010, 2012; Vichinsky et al, 2011; Vichinsky
et al, 2013).
The cause of these reversible creatinine increases has not
been fully elucidated, but a likely mechanism of action
appears to be the decrease in glomerular filtration rate (GFR)
that occurs as a result of the pharmacological effect of defer-
asirox on the intra-glomerular haemodynamics of the kidney
(Guo & Nzerue, 2002; Schetz et al, 2005). The underlying
mechanism for the increase in creatinine might also be
caused by an excess of drug relative to the amount of iron
available for chelation. It is possible that, in the absence of
sufficient chelatable excess iron, deferasirox removes enzy-
matic iron from one or more of the pathways that control
glomerular filtration. Rapid iron removal may lead to a cas-
cade of events following relative iron depletion (i.e. damage
to mitochondria in renal tubular cells, activation of the tubu-
loglomerular feedback and vasoconstriction) that culminate
in a reduction in GFR (Koren et al, 1991; Ponticelli et al,
2010; Musallam & Taher, 2012).
This Phase I, open-label study was therefore initiated to
assess the effects of deferasirox on measures of renal
function and markers of early kidney injury over the short
and long term. The working hypothesis was that deferasi-
rox produces a slight reduction in the GFR, an effect that
is reversible following interruption of deferasirox treat-
ment, thus indicating the absence of permanent nephron
damage.
Methods
Patients
Eligible patients were aged at least 18 years, had a diagnosis
of b thalassaemia major and were na€ıve to deferasirox treat-
ment. Patients were required to be receiving regular transfu-
sions at intervals of 2–5 weeks (iron intake ≥025 mg/kg/d)
and to have been administered at least 20 units of packed
red blood cells in their transfusion history. Iron overload was
also required for study inclusion, assessed as serum ferritin
levels ≥500 lg/l, or alternatively – if superconducting quan-
tum interference device (SQUID) was the regional standard
of care – using SQUID to measure liver iron concentration
(LIC) ≥2 mg Fe/g dry weight (dw).
Key exclusion criteria included serum creatinine concen-
trations greater than the upper limit of normal (ULN),
estimated creatinine clearance <60 ml/min [using the Cock-
croft–Gault formula (Cockcroft & Gault, 1976)], urinary pro-
tein:creatinine ratio >05 mg/mg, or alanine aminotransferase
exceeding 5 9 ULN. History of nephrotic syndrome or treat-
ment with drugs known to affect renal parameters also led to
exclusion from the study. Patients provided written informed
consent prior to entry.
Study design and treatment
This was an open-label, Phase I, single-arm study
(NCT00560820) of deferasirox in patients with b thalassae-
mia and transfusional iron overload, which was conducted
between 13 September 2007 and 24 April 2012 across three
Italian centres. Study protocols were approved by the rele-
vant ethics committees at each study site. The study was con-
ducted according to the International Conference on
Harmonisation Good Clinical Practice guidelines and the
Declaration of Helsinki. The study and any amendments
were reviewed by the Independent Ethics Committee or
Institutional Review Board for each centre.
The original planned study duration of 8 weeks was
extended to 108 weeks following a protocol amendment to
enable the collection of longer-term data. Thus, the 108-week
study comprised screening, initial treatment (8 weeks),
extended treatment (94 weeks) and washout periods
(2 weeks after Week 8 and 4 weeks after Week 104; Fig 1).
During the first treatment period of 8 weeks, all patients
received deferasirox 30 mg/kg/d, at least 30 min before a
meal. Dose adjustments and interruptions were permitted
after Week 10 for changes related to weight, serum ferritin
or safety parameters. Regular medications required to treat
concomitant conditions were allowed during the study.
Study objectives
The primary objective of this study was to estimate the
effects of deferasirox on changes from baseline in GFR and
renal plasma flow (RPF), as well as the corresponding fil-
tration fraction (FF; ratio of glomerular filtration rate
[GFR] to [RPF]), in deferasirox-na€ıve patients with regu-
larly transfused b thalassaemia and transfusional iron over-
load.
Secondary objectives were to explore the relationship
between change in serum creatinine and renal markers (GFR,
RPF and FF), and the association between changes in serum
ferritin levels and renal markers and serum creatinine. An
additional exploratory objective was to evaluate the effects of
deferasirox on urinary biomarkers.
Assessments
Changes from baseline in GFR and RPF were evaluated using
plasma sampling and radiotracers [51Cr-labelled ethylenedi-
aminetetraacetic acid (51Cr-EDTA) and ortho-123iodohippu-
rate (123I-OIH), respectively] (Nakashima et al, 1996;
Fleming et al, 2004). A trace dose of 123I-OIH (37 kBq/kg)
was administered intravenously into a forearm vein with an
insulin syringe. After 44 min, a venous blood sample was
drawn from the opposite arm of the 123I-OIH administra-
tion. A trace dose of 51CrEDTA (37 kBq/kg) was then
administered with an insulin syringe. Venous blood samples
were subsequently drawn at 120, 180 and 240 min after
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51Cr-EDTA administration from the opposite arm to the
infusion. The gamma-counter radioisotopic measurement
from blood samples was performed on the same day of the
test for 123I-OIH and after at least 48 h for 51Cr-EDTA. GFR
and RPF assessments were performed at baseline and Weeks
2, 8, 10, 52, 104 and 108. The corresponding FF was calcu-
lated from the ratio of GFR to RPF.
Blood samples for measurement of serum creatinine were
drawn at baseline, Weeks 1–4, 8 and 10, and monthly there-
after. Estimated creatinine clearance was calculated according
to creatinine levels, age and body mass using the Cockcroft–
Gault formula (Cockcroft & Gault, 1976). Serum ferritin lev-
els were measured by blood sampling at screening, baseline,
Weeks 2, 8 and 10, and monthly thereafter. LIC was mea-
sured by SQUID at baseline.
A panel of protein markers measured by Rules Based
Medicine (RBM; Austin, TX, USA), called the Human Kid-
neyMAP, was assessed in urine samples. Samples for biomar-
ker analysis were collected at screening, baseline, Weeks 2, 4,
8 and 10, and monthly thereafter. RBM’s Human Kidney
MAP utilizes a multiplexed panel of biomarkers to detect
early signs and locations of drug-induced kidney damage.
The renal biomarkers included in this study were glutathione
S-transferase-pi (GST-pi), microalbumin, neutrophil gelati-
nase-associated lipocalin (NGAL) and kidney injury mole-
cule-1 (KIM-1). In addition, the panel included
measurement of urine creatinine, which was used for nor-
malization.
Additional safety assessments comprised adverse event
(AE) reporting (including serious AEs) and regular monitor-
ing of haematology, blood chemistry, urine, vital signs, phys-
ical condition and body weight. Safety was assessed weekly
up to Week 4 and fortnightly up to Week 10, then monthly
thereafter.
Statistical methods
The planned enrollment was for 16 patients. However, chal-
lenges were experienced during enrollment; namely, the lim-
ited number of patients with b thalassaemia who were
deferasirox-na€ıve and willing to undergo the demanding and
invasive assessments of the study.
Analyses of renal measures and urinary biomarkers were
performed in the full analysis set, which included all patients
who passed screening and were enrolled in the study. The
safety set comprised all patients who were enrolled and
received at least one dose of deferasirox and who had at least
one post-baseline measurement.
Results for mean change in renal haemodynamic and
safety measures are presented descriptively. Absolute and per-
centage changes from baseline in GFR, RPF and FF were cal-
culated using a linear mixed-effects model with visit as a
fixed effect and patient as a random factor. The relationship
between serum creatinine or serum ferritin and renal markers
(GFR, RPF and FF) was tested using a linear or non-linear
mixed-effects model with renal markers as dependent vari-
ables and change in serum ferritin or serum creatinine as
fixed factors. Statistical software used was SAS version 9.2
(SAS Institute Inc., Cary, NC, USA). No P-values were calcu-
lated as the study was neither designed nor powered to
detect statistical differences between baseline and post-treat-
ment measurements.
In the exploratory analysis, levels of urinary biomarkers
were normalized to urinary creatinine, a procedure routinely
used to account for the wide between- and within-individual
variation in urinary flow rates.
Results
Patient disposition
Eleven patients were enrolled in the study. During the short-
term 10-week study period (8-week treatment and 2-week
washout), one patient discontinued due to consent with-
drawal; 10 patients completed the short-term study. Of these,
five patients did not enter the extension trial as they com-
pleted the initial trial prior to the approval of the protocol
amendment extending the study duration. Five patients in
total completed the 108-week study duration.
Patient characteristics
Baseline characteristics (n = 11) are shown in Table I.
Patients were a mean age of 352 years, were all Caucasians
Fig 1. Study design. *GFR and RPF measured using 51Cr-EDTA and 123I-OIH. BL, baseline; 51Cr-EDTA, 51Cr-labelled ethylenediaminetetraacetic
acid; GFR, glomerular filtration rate; 123I-OIH, ortho-123iodohippurate; RPF, renal plasma flow.
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and predominantly males (636%). All patients demonstrated
iron overload at baseline, as indicated by a median (range)
serum ferritin level of 2110 lg/l (840–3131 lg/l) and
mean  standard deviation (SD) LIC of 73  40 mg Fe/
g dw. Mean GFR, RPF and FF values were in the normal
range for all patients at baseline (Table I).
Exposure to deferasirox
Overall, six (545%) patients were exposed to deferasirox for
<3 months, two(182%)patients for 24 to<27 months and three
(273%)patients receiveddeferasirox for27 monthsor longer.
Change in GFR, RPF and FF
Short-term 10-week study. Median serum ferritin level was
2110 lg/l (range 840–3131 lg/l) at baseline and 2035 lg/l
(range 1100–3082 lg/l) at Week 10.
The mean GFR change at Week 8 from baseline was
158  122 ml/min (141%; Fig 2A). A mean decrease of
910  533 ml/min (149%) versus baseline was observed
in RPF (Fig 2B). Following 2 weeks of washout (Week 10),
both GFR and RPF returned to near baseline values. At Week
10, mean changes of 04  87 ml/min (01%) and
432  796 ml/min (69%) were observed for GFR and
RPF, respectively, compared with baseline (Fig 2A, B).
Mean  SD FF demonstrated mild fluctuations from baseline
through Week 10 (mean change at Week 8: 0003  003,
20%; Week 10: 001  002, 82%; Fig 2C).
Mean  SD serum creatinine concentrations increased from
baseline to Week 8 by 126  108 lmol/l (214%; Fig 3A). Fol-
lowing washout (Week 10), serum creatinine levels declined to
close to baseline levels, as demonstrated by a mean change of
05  74 lmol/l (19%) from baseline (Fig 3A). Similar to
GFR, estimated creatinine clearance decreased at Week 8 (mean
change: 214  193 ml/min, 162%) but returned to base-
line values after washout (mean change: 23  173 ml/min,
10%; Fig 3B).
Long-term 108-week study. Median serum ferritin levels
decreased from 2110 lg/l (range 840–3131 lg/l) at baseline
to 1050 lg/l (range 509–3375 lg/l) at Week 108.
Among the five patients who completed the 108-week
study, decreases from baseline to Week 8 were observed in
GFR (mean absolute change: 92  104 ml/min; 95%)
and RPF (1057  472 ml/min; 178%; Fig 2A, B). After
the 2-week washout period at Week 10, both GFR and RPF
returned to close to baseline values. Accordingly, a mean
increase of 35  119 ml/min (21%) for GFR and a mean
decrease in RPF of 524  1069 ml/min (90%) were
observed at Week 10 compared with baseline.
After Week 10, treatment was re-initiated. In the following
assessmentatWeek52,meanGFRandRPFweredecreased(mean
change:191  80 ml/min,177% and1556  159 ml/
min, 261%, respectively). GFR and RPF stabilized between
Week 52 andWeek 104. Therefore, mean changes from baseline
to Week 104 were 184  32 ml/min for GFR and
1159  743 ml/min for RPF, which were equivalent to a
decrease of 172% and 196%, respectively. Following the 4-week
washout period (Week 108), both measures recovered to near
baseline values. Thus, at Week 108, mean change from baseline
for GFR was50  35 ml/min (45%) and 419  665
ml/min(73%)forRPF.
Mean FF showed only minor fluctuations (018–021) dur-
ing the study (mean change at Week 104: 001  002, 43%;
Week 108: 001  003, 52%; Fig 2C).
Among the five patients who completed the 108-week study,
serum creatinine was elevated at Week 8 (mean change:
92  100 lmol/l, 181%), while mean creatinine clearance
decreasedby177  227 ml/min(137%).AtWeek10post-
washout, absolute changes in both of these measures reflected a
return to baseline levels (mean serum creatinine:
11  110 lmol/l, 07%; mean creatinine clearance:
01  264 ml/min, 16%; Fig 3A, B). Mean creatinine levels
stabilized from Week 52 onwards (Fig 3A, B). At Week 104,
changes in serum creatinine and creatinine clearance were 72%
and 57%, respectively, compared with baseline. As observed
for other measures of renal function, washout resulted in rever-
sion of both serum creatinine and creatinine clearance to almost
baseline levels at Week 108 (mean change: 14  104 lmol/l,
53%and51 224 ml/min,20%,respectively).
Urinary biomarkers
Results from exploratory analyses in five patients revealed
modest variations (less than one order of magnitude) in
microalbumin, NGAL, KIM-1 and GST-pi, with deferasirox
treatment. No apparent trend for increasing biomarker levels
with time was observed in the four patients who were treated
Table I. Demographics and baseline characteristics for patients in
the short-term 10-week study.
Patients (n = 11)
Age, mean (range), years 352 (24–48)
Males:females, n 7:4
Caucasian, n (%) 11 (100)
Hispanic/Latino:other 3:8
Weight, mean  SD, kg 612  116
BMI, mean  SD, kg/m2 233  40
Characteristic
Serum ferritin, median (range), lg/l 2110 (840–3131)
LIC, mean  SD, mg Fe/g dw 73  40
GFR, mean  SD, ml/min 1115  175
RPF, mean  SD, ml/min 6035  943
FF, mean  SD 019  003
Serum creatinine, mean  SD, lmol/l 620  141
Creatinine clearance, mean  SD, ml/min 1217  168
BMI, body mass index; FF, filtration fraction; GFR, glomerular filtra-
tion rate; LIC, liver iron concentration; RPF, renal plasma flow; SD,
standard deviation.
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for 266–342 d and in the remaining patient for whom data
were available up to Week 108.
Serum creatinine, creatinine clearance and serum ferritin
versus renal and urinary markers
As a result of the limited number of patients available for
analysis, no clear trend in the relationship between changes
in serum creatinine, creatinine clearance or serum ferritin
and renal markers could be established. Overall, results
suggest that the decrease in GFR and RPF was accompanied
by a small increase in serum creatinine and a decrease in cre-
atinine clearance. A consistent association between changes
in serum creatinine and changes in urinary biomarkers was
also not apparent because of the small patient sample.
Safety
All patients (n = 11) experienced at least one AE. There were
no deaths or serious AEs reported during the 108-week
(A)
(B)
(C)
Fig 2. Mean  SD renal haemodynamic mea-
sures over time in patients receiving short-
(n = 11) and long-term (n = 5) deferasirox
treatment: (A) GFR; (B) RPF; (C) FF. BL, base-
line; FF, filtration fraction; GFR, glomerular fil-
tration rate; RPF, renal plasma flow; SD,
standard deviation.
A. Piga et al
886 ª 2014 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2015, 168, 882–890
study. Common AEs (≥10% of patients) regardless of study
drug relationship included upper abdominal pain, cough,
diarrhoea, oropharyngeal pain, pyrexia and rhinitis (all
n = 3, 273%). Overall, two patients had AEs (upper abdom-
inal pain, rash and pruritus), which were suspected by the
investigator to be treatment related. In the patient with rash
and pruritus, treatment with deferasirox was temporarily
interrupted and then resumed once the event was resolved.
The second patient had upper abdominal pain and rash,
which resolved in 4 and 8 days, respectively.
There were no significant changes in haematological
parameters, vital signs or aspartate aminotransferase through-
out the study duration. Alanine aminotransferase in patients
who completed the long-term study (n = 5) remained nor-
mal throughout, with a mean  SD at baseline of
296  155 u/l and at Week 108 of 344  246 u/l.
Discussion
Patients with b thalassaemia major are at potential risk of renal
dysfunction as a result of their disease, transfusional iron over-
load and/or chelation therapy (Ponticelli et al, 2010; Bhandari
& Galanello, 2012). In some patients treated with deferasirox,
small increases in serum creatinine – mostly mild and typically
dose-dependent – have been observed (Cappellini et al, 2006,
2010, 2011; Galanello et al, 2006; Vichinsky et al, 2007; Porter
et al, 2008; Pennell et al, 2010, 2012; Vichinsky et al, 2011).
Although these changes are largely reversible with dose reduc-
tion and/or interruption, it is important to understand the
mechanism of the effects of deferasirox, which may help us to
understand whether there is a risk of any progressive worsen-
ing of renal function. In addition, preclinical studies have sug-
gested that the renal effects of deferasirox may be due to a
direct action on renal tubular cells, although these findings
could not be repeated in a human cell line (Sanchez-Gonzalez
et al, 2011). This study, therefore, aimed to evaluate the short-
and long-term effects of deferasirox on renal haemodynamics
in patients with b thalassaemia major. Over a total study
duration of 108 weeks, deferasirox was associated with a mild
reversible haemodynamic effect on renal function, as measured
by GFR, RPF, FF, serum creatinine and creatinine clearance.
Decreases in GFR and RPF were observed at Week 8 in the
short-term study and up to Week 52 in the long-term study. A
similar pattern of change was noted for serum creatinine and
creatinine clearance. Although there were no assessments
between Week 10 and Week 52, all renal parameters were seen
to stabilize between Week 52 and Week 104. Importantly, renal
measures recovered to near baseline values after washout at
both short- and long-term endpoints. This suggests, firstly, a
reversibility of treatment effect, and, secondly, no progressive
(A)
(B)
Fig 3. Mean  SD (A) serum creatinine and
(B) creatinine clearance over time in patients
receiving short- (n = 11) and long-term
(n = 5) deferasirox treatment. BL, baseline; SD,
standard deviation.
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worsening of renal function with up to 2 years of treatment
with deferasirox.
In this study, there was no clear trend in the relationship
between the measured renal parameters and serum creatinine
or creatinine clearance, despite observations suggesting that
decreases in GFR and RPF were accompanied by a small
increase in serum creatinine and decrease in creatinine clear-
ance. In addition, no consistent pattern of changes was
detected when serum ferritin was plotted against GFR, RPF
and FF. Other studies have also noted a lack of correlation
between serum ferritin changes and changes in GFR, but
have shown significant correlation between serum ferritin
and N-acetyl beta-D-glucosaminidase (NAG) activity (Jalali
et al, 2011). While the small sample population is a likely
explanation for the observed lack of correlation, the possibil-
ity exists that an inconsistent relationship between measured
parameters reflects the mild and transient effect of deferasi-
rox on renal haemodynamics. It should also be noted that
the results from this exploratory analysis are presented
descriptively, as the study was neither designed nor powered
to detect statistical differences between different populations.
It is interesting to note that the patient population in this
study was both older (being restricted to adult patients as a
result of the invasive nature of the study) and had a lower
than average iron burden than the general b thalassemia
population. We may speculate that these two factors increase
susceptibility to renal complications in these patients; this
may add value to our finding that deferasirox is associated
with only a mild reversible haemodynamic effect on renal
function, which is of interest to clinical practice. Further-
more, although the small sample size signals caution in the
interpretation of our study findings, the observations in this
study are substantiated by results from larger clinical trials
(Cappellini et al, 2006, 2010, 2011; Galanello et al, 2006;
Vichinsky et al, 2007; Porter et al, 2008; Pennell et al, 2010,
2012; Vichinsky et al, 2011). In the first prospective trial to
monitor the long-term effects of deferasirox in children and
adults with b thalassaemia, mild and non-progressive
increases in serum creatinine were noted among patients
who received deferasirox treatment for up to 5 years (Cap-
pellini et al, 2011). The study also reported slight decreases
in creatinine clearance that did not progress beyond the first
6 months of treatment (Cappellini et al, 2011). During the
first year of this study, it was shown that the incidence of
creatinine elevations was highest in patients with low transfu-
sional iron intake who had the most dramatic decreases in
LIC and serum ferritin (Cappellini et al, 2006), although a
recent study has indicated that there is no overall increased
risk of renal toxicity in deferasirox-treated patients with LIC
<7 mg Fe/g dw, compared with those with LIC >7 mg Fe/
g dw (Porter et al, 2013). Nevertheless, the occurrence of
renal complications and the implications from preclinical
trials advocate that continual monitoring of both renal and
liver function during deferasirox treatment is carried out
(Novartis Pharmaceuticals 2013; Novartis Pharmaceuticals
UK Ltd, 2014) (http://www.medicines.org.uk/emc/medicine/
18805/; http://www.pharma.us.novartis.com/product/pi/pdf/
exjade.pdf), to ensure that risks of chelation are minimized.
Early identification of kidney damage is imperative to
minimize the potential for progressive renal injury (Guo &
Nzerue, 2002). Urinary biomarkers, such as GST-pi, KIM-1
and NGAL, have been shown to serve as reliable early indica-
tors of acute kidney injury (Koyner et al, 2010). In this
study, results from exploratory analyses of change in these
urinary biomarkers with deferasirox treatment did not show
significant elevations or a trend to increase over time, sug-
gesting the absence of acute or progressive kidney damage in
the small population investigated.
The safety profile of deferasirox among patients with b thal-
assaemia in this study was consistent with that observed in other
large studies, with AEs being mainly mild-to-moderate and gas-
trointestinal (Cappellini et al, 2010, 2011). With relevance to
renal function and in agreement with prior long-term reports in
thalassaemia (Cappellini et al, 2011), none of the patients dis-
continued the study because of serum creatinine increases.
In conclusion, our results showed that in patients with no
pre-existing renal dysfunction or disease, deferasirox appears
to produce a mild effect on renal haemodynamics, which was
reversible after drug interruption over the short and long
term, with no progressive worsening of renal function.
Despite the limited sample size, these findings contribute to
accumulating evidence supporting a favourable long-term
risk:benefit profile for deferasirox in the treatment of transfu-
sional iron overload.
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